Kelly A Soderberg
Overview
Explore the profile of Kelly A Soderberg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
2921
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Moody M, Pedroza-Pacheco I, Vandergrift N, Chui C, Lloyd K, Parks R, et al.
Sci Immunol
. 2017 Aug;
1(1):aag0851.
PMID: 28783677
Induction of broadly neutralizing antibodies (bnAbs) is a goal of HIV-1 vaccine development. bnAbs occur in some HIV-1-infected individuals and frequently have characteristics of autoantibodies. We have studied cohorts of...
2.
Santra S, Tomaras G, Warrier R, Nicely N, Liao H, Pollara J, et al.
PLoS Pathog
. 2015 Aug;
11(8):e1005042.
PMID: 26237403
HIV-1 mucosal transmission begins with virus or virus-infected cells moving through mucus across mucosal epithelium to infect CD4+ T cells. Although broadly neutralizing antibodies (bnAbs) are the type of HIV-1...
3.
Sarzotti-Kelsoe M, Needham L, Rountree W, Bainbridge J, Gray C, Fiscus S, et al.
J Immunol Methods
. 2014 Jun;
409:21-30.
PMID: 24910414
The Center for HIV/AIDS Vaccine Immunology (CHAVI) consortium was established to determine the host and virus factors associated with HIV transmission, infection and containment of virus replication, with the goal...
4.
Zolla-Pazner S, deCamp A, B Gilbert P, Williams C, Yates N, Williams W, et al.
PLoS One
. 2014 Feb;
9(2):e87572.
PMID: 24504509
Unlabelled: In the RV144 HIV-1 vaccine efficacy trial, IgG antibody (Ab) binding levels to variable regions 1 and 2 (V1V2) of the HIV-1 envelope glycoprotein gp120 were an inverse correlate...
5.
Apps R, Qi Y, Carlson J, Chen H, Gao X, Thomas R, et al.
Science
. 2013 Apr;
340(6128):87-91.
PMID: 23559252
A variant upstream of human leukocyte antigen C (HLA-C) shows the most significant genome-wide effect on HIV control in European Americans and is also associated with the level of HLA-C...
6.
Liao H, Lynch R, Zhou T, Gao F, Alam S, Boyd S, et al.
Nature
. 2013 Apr;
496(7446):469-76.
PMID: 23552890
Current human immunodeficiency virus-1 (HIV-1) vaccines elicit strain-specific neutralizing antibodies. However, cross-reactive neutralizing antibodies arise in approximately 20% of HIV-1-infected individuals, and details of their generation could provide a blueprint...
7.
Freel S, Picking R, Ferrari G, Ding H, Ochsenbauer C, Kappes J, et al.
J Virol
. 2012 Apr;
86(12):6835-46.
PMID: 22514337
CD8-mediated virus inhibition can be detected in HIV-1-positive subjects who naturally control virus replication. Characterizing the inhibitory function of CD8(+) T cells during acute HIV-1 infection (AHI) can elucidate the...
8.
Thomas R, Thio C, Apps R, Qi Y, Gao X, Marti D, et al.
J Virol
. 2012 Apr;
86(12):6979-85.
PMID: 22496224
Variants near the HLA-DP gene show the strongest genome-wide association with chronic hepatitis B virus (HBV) infection and HBV recovery/persistence in Asians. To test the effect of the HLA-DP region...
9.
Haynes B, B Gilbert P, McElrath M, Zolla-Pazner S, Tomaras G, Alam S, et al.
N Engl J Med
. 2012 Apr;
366(14):1275-86.
PMID: 22475592
Background: In the RV144 trial, the estimated efficacy of a vaccine regimen against human immunodeficiency virus type 1 (HIV-1) was 31.2%. We performed a case-control analysis to identify antibody and...
10.
Gnanakaran S, Bhattacharya T, Daniels M, Keele B, Hraber P, Lapedes A, et al.
PLoS Pathog
. 2011 Oct;
7(9):e1002209.
PMID: 21980282
Here we have identified HIV-1 B clade Envelope (Env) amino acid signatures from early in infection that may be favored at transmission, as well as patterns of recurrent mutation in...